Roivant Sciences (FRA:87S) Quality Rank


FRA:87S Roivant Sciences Ltd FRA:87S
51 GF Score
Price €31.20
GF Value €9.34
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Roivant Sciences Quality Rank?

The Quality Rank measures the business quality of a company relative to other companies. It is ranked based on the strength of the balance sheet, as well as the profitability and growth of the business. The ranked companies are split in equal numbers and then ranked from 1 to 10, with 10 being the highest.

The rank of balance sheet (30%)

The rank of balance sheet is done through the ranking of:
  • Interest coverage
  • Zscore
  • Debt to revenue
  • Equity to asset
  • Cash to debt

The rank of Profitability (70%)

The ranking of Profitability is done by ranking:
  • Operating margin mean rank (10-year mean average profit margine)
  • Operating margin growth rank
  • Fscore
  • Predictability rank
  • Revenue growth rank (5 year), when the growth is higher than 25%, set it as 25%
  • Num of year profit (number of years that is profitable within the last 10 years)
  • ROIC median (10-year median of ROIC)

Roivant Sciences Quality Rank Related Terms

FRA:87S
51GF Score
Roivant Sciences Ltd FRA:87S
Quality Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Roivant Sciences (FRA:87S) Overvalued in 2026?

Based on GuruFocus' analysis, Roivant Sciences stock appears to be overvalued. The current stock price of €31.20 is trading 234% above its estimated GF Value™ of €9.34. GuruFocus considers Roivant Sciences to be Significantly Overvalued.

Key valuation signals for FRA:87S:

  • Quality Rank:
  • GF Value™: €9.34 vs. price of €31.20 (234% above fair value)
  • GF Score™: 51/100 with 7 warning signs

No single metric tells the full story. See the FRA:87S stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Roivant Sciences Business Description

Other Exchanges ROIV:USA87S:Germany
Address 50 Broadway, 7th Floor, London, GBR, SW1H 0BD
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
51GF Score

Get the complete analysis for FRA:87S

Quality Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€31.20
Price
€9.34
GF Value